Cannabis, ovulation and fertility: why more cannabinoids are not necessarily better

Fertility depends on precisely timed events

Conception requires coordinated follicle development, oocyte maturation, ovulation, fertilization, embryo transport and uterine receptivity. Research models indicate that the endocannabinoid system (ECS) contributes to several of these stages. That is precisely why exposure to external cannabinoids while trying to conceive requires care: a system that needs finely tuned signaling is not necessarily helped by extra stimulation.

Anandamide changes across the cycle

Research in humans has found that circulating anandamide can fluctuate with menstrual phases and may be highest around ovulation, alongside changes in estradiol and gonadotrophins. Components of the ECS have also been identified in human ovarian tissues and follicular fluid. These observations suggest a physiological role for the body's own signaling molecules. They do not demonstrate that THC improves ovulation or that a higher cannabinoid level is always desirable.

Natural endocannabinoids and THC are not equivalent

Anandamide is synthesized locally, acts in a particular environment and is broken down by enzymes such as FAAH. THC consumed in a cannabis product reaches many tissues, has different persistence and can activate CB1 in ways that do not reproduce the local physiological signal. A hormone can be essential without extra hormone being beneficial; the same principle applies to endocannabinoid pathways.

What human evidence says about ovulation and conception

Research on cannabis and menstrual-cycle or ovulatory outcomes is limited and sometimes conflicting. The American Society for Reproductive Medicine (ASRM) reviewed studies in its 2024 committee opinion and did not find a consistent association between marijuana use and female or male fecundability (the chance of conception in a menstrual cycle), reproductive hormone levels or assisted-reproduction outcomes. Some individual studies suggest possible risks, while others find no clear association. Inconsistent findings should neither be turned into certainty of harm nor into a declaration of safety.

What IVF studies can and cannot establish

Research in people undergoing assisted reproductive treatment has generally involved small numbers of cannabis-exposed participants. Some studies found no statistically significant difference in implantation, pregnancy or live birth, and others raised different concerns. The estimates are too imprecise to identify a safe exposure level, and products, frequency and timing are often incompletely recorded. A positive pregnancy test is also only one outcome; early development and pregnancy course matter.

Implantation involves a particularly delicate balance

Laboratory and animal studies indicate that endocannabinoid signaling can influence embryo transport and implantation. Excessive pathway activation has disrupted reproductive processes in some models. These findings are biologically important but cannot be translated directly into an exact human THC threshold or a definitive risk percentage. Human observational research cannot capture every relevant reproductive step.

CBD is not automatically safe for fertility

CBD lacks the typical intoxicating effects of THC, but is still pharmacologically active and can interact with enzymes and medications. There are insufficient clinical data to establish that CBD products are safe or beneficial while trying to conceive, during pregnancy or while breastfeeding. Product labels may not reliably capture all exposures. Do not assume that an over-the-counter or "non-intoxicating" preparation is harmless.

Pregnancy planning changes the decision

Someone using cannabis for endometriosis pain, sleep or another condition may experience symptom relief and still need to weigh potential reproductive exposure. Obstetric guidance recommends avoiding cannabis when planning pregnancy, during pregnancy and while breastfeeding. Clinicians can help arrange alternative care for the symptoms that prompted its use. No reliable universal rule identifies a safe dose, frequency or number of days before ovulation at which exposure ceases to matter. An individual medication and symptom plan should be discussed with the treating medical team.

Key conclusion

The ECS is important in reproductive biology, but that is not an argument for taking THC or CBD to enhance fertility. Human fertility data on cannabis are heterogeneous and limited; possible effects on ovulation, implantation and pregnancy warrant caution. The responsible message is to distinguish basic mechanisms from clinical outcomes and to seek individualized advice when pregnancy is planned or possible.

Original references and Hebrew article

This article is an editorial adaptation of the Hebrew original.

1. Cameron RS, et al. The impact of cannabinoids on reproductive function. Reproduction. 2025. Find publication ↗
2. American Society for Reproductive Medicine. Tobacco or marijuana use and infertility: a committee opinion. 2024. Find publication ↗
3. El-Talatini MR, Taylor AH, Konje JC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertility and Sterility. 2010;93(6):1989–1996. Read the publication ↗
4. El-Talatini MR, et al. Localisation and function of the endocannabinoid system in the human ovary. Find publication ↗
5. Effects of Phytocannabinoids on Reproductive System and Prenatal Development: Mechanisms and Clinical Implications. 2025. Find publication ↗
6. ASRM committee opinion, tobacco or marijuana use and infertility (2024) Find publication ↗

Read original Hebrew article ↗

Educational information only. This page is not a diagnosis or a treatment recommendation. Do not alter prescribed care without consulting the treating clinician, especially in neurological illness, fertility planning or pregnancy.

ACOG guidance on cannabis, pregnancy and lactation ↗